Haemophilus influenzae b polysaccharide-tetanus conjugate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Haemophilus influenzae b polysaccharide-tetanus conjugate
DrugBank Accession Number
DB15876
Background

Not Available

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Conjugate
Synonyms
  • Haemophilus influenzae b polysaccharide - tetanus conjugate
  • Haemophilus influenzae b polysaccharide-tetanus conjugate
  • Haemophilus influenzae type b polysaccharide conjugated to tetanus protein
  • Haemophilus influenzae type b polysaccharide conjugated to the tetanus protein

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HexacimaHaemophilus influenzae b polysaccharide-tetanus conjugate (29 mcg) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU) + Hepatitis B Vaccine (Recombinant) (10 mcg) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D-antigen Units) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 D-antigen Units) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D-antigen Units)Injection, suspensionIntramuscularSanofi Pasteur2021-03-18Not applicableEU flag
HEXAXIMHaemophilus influenzae b polysaccharide-tetanus conjugate (12 mcg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (20 IU/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 mcg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5ml)Injection, suspensionIntramuscularบริษัท ซาโนฟี่ ปาสเตอร์ จำกัด2017-05-31Not applicableThailand flag
INFANRIX - IPV+HIbHaemophilus influenzae b polysaccharide-tetanus conjugate (10 μg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 μg/0.5ml) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (8 μg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (25 μg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5ml)Injectionบริษัท แกล็กโซสมิทไคล์น (ประเทศไทย) จำกัด2003-11-01Not applicableThailand flag
INFANRIX HEXAHaemophilus influenzae b polysaccharide-tetanus conjugate (10 mcg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg/0.5ml) + Bordetella pertussis pertactin antigen (8 mcg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 mcg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5ml)Injectionบริษัท แกล็กโซสมิทไคล์น (ประเทศไทย) จำกัด2005-05-26Not applicableThailand flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Haemophilus Influenzae Serotype b (Hib) / Poliomyelitis / Tetanus / Viral Hepatitis B1
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Poliomyelitis / Tetanus1
4CompletedPreventionDiphtheria / Haemophilus Infections / Pertussis / Poliomyelitis / Tetanus1
4CompletedPreventionDiphtheria / Haemophilus Influenzae Serotype b (Hib) / Pertussis / Poliomyelitis / Tetanus1
4CompletedPreventionDiphtheria / Pertussis / Poliomyelitis / Tetanus1
4CompletedPreventionDrug Therapy, Combination / Fever, Chemically Induced / Infants / Vaccines, Pneumococcal1
4CompletedPreventionPertussis1
4CompletedPreventionStreptococcal Infections1
4CompletedPreventionVaccines, Pneumococcal1
4RecruitingPreventionDiphtheria1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for suspensionIntramuscular
Injection, suspensionIntramuscular
Injection, powder, for solutionIntramuscular
Injection, powder, for solutionIntramuscular25 µg
Injection
SuspensionIntramuscular
Injection, powder, for suspensionIntramuscular
Solution / dropsOral
InjectionIntramuscular
Injection, powder, for suspensionIntramuscular25 mcg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 23, 2020 16:20 / Updated on September 24, 2020 11:24